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Charlotte Rees13,14, Mairéad G. McNamara15,16, Sandy Beare2, John A. Bridgewater 17, Caroline Dive1 and Juan W. Valle 15,16
BACKGROUND: Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem],
improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive
biomarkers predictive of cediranib beneﬁt may improve patient outcomes.
METHODS: Changes in 15 circulating plasma angiogenesis or inﬂammatory-related proteins and cytokeratin-18 (CK18), measured
at baseline and during therapy until disease progression, were correlated with overall survival (OS) using time-varying covariate Cox
models (TVC).
RESULTS: Samples were available from n= 117/124 (94%) patients. Circulating Ang1&2, FGFb, PDGFbb, VEGFC, VEGFR1 and CK18
decreased as a result of the therapy, independent of treatment with cediranib. Circulating VEGFR2 and Tie2 were preferentially
reduced by cediranib. Patients with increasing levels of VEGFA at any time had a worse PFS and OS; this detrimental effect was
attenuated in patients receiving cediranib. TVC analysis revealed CK18 and VEGFR2 increases correlated with poorer OS in all
patients (P < 0.001 and P= 0.02, respectively).
CONCLUSIONS: Rising circulating VEGFA levels in patients with ABC, treated with CisGem, are associated with worse PFS and OS,
not seen in patients receiving cediranib. Rising levels of markers of tumour burden (CK18) and potential resistance (VEGFR2) are
associated with worse outcomes and warrant validation.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0132-8
INTRODUCTION
Novel therapeutic options, based on an improved understanding
of underlying biology and response to therapy, are urgently
needed for patients presenting with advanced biliary tract cancer
(ABC). Whilst uncommon in the developed world, biliary tract
cancer (BTC including cholangiocarcinoma [CCA], gallbladder and
ampullary carcinoma) represent a signiﬁcant global problem due
to areas of high incidence, for instance of liver ﬂuke-associated
cholangiocarcinoma in Northern Thailand1 and of gallbladder
cancer in Chile and India.2
Surgery is the cornerstone of curative therapy for BTC; the use
of adjuvant therapy has historically been based on meta-analyses
of non-randomised series and prospective studies.3 The recently
presented phase III, randomised, BilCap study has demonstrated
an overall survival (OS) beneﬁt from the use of adjuvant use of oral
capecitabine following surgery versus surgery alone.4 Unfortu-
nately, most patients are present with advanced (non-resectable
or metastatic) disease and their survival is ≤3 months, with best
supportive care alone.5 In the ABC-02 study,6 the combination
chemotherapy with cisplatin and gemcitabine achieved a median
survival of 11.7 months, compared to gemcitabine monotherapy
(8.0 months; HR= 0.64, 95% conﬁdence interval (CI) 0.52–0.80; P <
0.001), ﬁndings which were conﬁrmed in the Japanese
BT22 study.7 Although this is the international reference regimen,8
there is a pressing need to improve the efﬁcacy, given these
modest outcomes.
Angiogenesis is one of the hallmarks of neoplasia; the expression
of vascular endothelial growth factor (VEGF) is associated with
www.nature.com/bjc
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adverse clinical features including the presence of liver metastases
in intra-hepatic cholangiocarcinoma (iCCA)9 and increased micro-
vessel density (MVD) in both gallbladder cancer10 and CCA.11 In
patients undergoing curative resection, MVD has been identiﬁed as
an independent prognostic risk factor for OS in lymph node-
negative iCCA12 and gallbladder cancer,13 as well as for disease-free
survival (DFS)13 and OS14 in patients with extrahepatic cholangio-
carcinoma (eCCA). These clinical observations are consistent with
the demonstration of receptors for VEGF (VEGFR1 and VEGFR2) in
tumour proximal endothelial cells15 along with the frequent
(40–75%) expression of VEGF (particularly VEGFA) in BTC 9-,11
particularly at the invasive edge of the tumour.13
Cediranib is an oral VEGFR1, VEGFR2 and VEGFR3 tyrosine kinase
inhibitor (TKI), with additional activity against platelet-derived
growth factor (PDGF) receptors and c-KIT.16 In the prospective
randomised double blind placebo-controlled phase II ABC-03
study, the cisplatin and gemcitabine combination was evaluated
with either cediranib or placebo. Although an improved response
rate was observed (44% vs. 19% with placebo; P= 0.0036) along
with an improved 6-month progression-free survival (PFS, 70.5% vs.
61.3%; P < 0.05) in cediranib-treated patients, the magnitude of this
effect did not reach the pre-deﬁned level of statistical signiﬁcance
(hazard ratio [HR] for PFS: 0.93, 80% CI 0.74–1.19; P= 0.72) for the
primary endpoint. This may have been due to lack of efﬁcacy, or
alternatively, underpowering of the statistical plan, or because
cediranib was not well tolerated in this combination.17
Recognising the challenge of serial tumour biopsy, an
exploratory translational endpoint of the ABC-03 study was the
prospective longitudinal proﬁling of circulating biomarkers
associated with angiogenes
is. We now present the ﬁndings of this work, set the ﬁndings in
context and evaluate the implications for future clinical trials.
MATERIALS AND METHODS
Patients and treatment
ABC-03 (clinicaltrials.gov NCT0939848) was an investigator-initiated,
multi-centre (15 UK sites), double-blind, placebo-controlled, rando-
mised phase II study of cediranib added to the standard-of-care
chemotherapy regimen (cisplatin and gemcitabine), the details of
which have been described previously.17 Permission for this trial was
granted by the North West 5 Research Ethics Committee, Haydock
Park on 23 August 2010 (10/H1010/42). All patients provided written
informed consent before randomisation.
Material collection and analysis
Blood samples were collected from the patients for biomarker
studies into EDTA tubes and processed into plasma at up to 11
timepoints; two pre-treatment baseline samples and then on the
ﬁrst day of cycles 2–8, at the end of chemotherapy and 1-month
after the end of chemotherapy. The circulating markers of
angiogenesis (VEGFA, VEGFC, VEGFR1, VEGFR2, angiopoietins 1
and 2 [Ang1, Ang2], ﬁbroblast growth factor b [FGFb], hepatocyte
growth factor [HGF], PDGFbb, keratinocyte growth factor [KGF],
placental growth factor [PlGF], tyrosine kinase with Ig and EGF
homology domains 2 [Tie2], stromal-derived growth factor 1b
[SDF1b]) and inﬂammation (interleukin 6 and interleukin 8 [IL6
and IL8]) were measured with a validated18 multiplex enzyme-
linked immune-sorbent assay [ELISA] platform (Aushon BioSys-
tems, Billerica, Massachusetts, USA), according to the Good Clinical
Practice (GCP) standards at the Cancer Research UK Manchester
Institute (Manchester, UK). Concentrations of the circulating total
cytokeratin18 (CK18),19 released from epithelial cells during death
(apoptosis and necrosis), were measured with an M65 ELISA
(Peviva, Nacka, Sweden), also previously validated and implemen-
ted to GCP as previously described.20
Whole-blood (10 mL) was collected in CellSave Preservative
Tubes at up to four time points (pre-treatment baseline sample, on
day 1 of cycles two and ﬁve, and 1-month after the end of
chemotherapy) for the enumeration of circulating tumour cells
(CTCs) with the CellSearch platform (Janssen Diagnostics, South
Raritan, New Jersey, USA) within 4 days of blood draw.21 Brieﬂy,
after immunomagnetic capture of EpCAM-positive cells, immuno-
phenotyping of cells with an intact (4′,6-diamidino-2-phenylindole
[DAPI] stained) nucleus using antibodies cytokeratin (CK) and
CD45 allowed the classiﬁcation of circulating tumour cells as
EpCAM+, CK+, DAPI+ and CD45−.
All collected samples were analysed, unless the samples were
not available for clinical reasons or patient discontinuation from
the study (per protocol).
Statistical methods
Two aliquots of each plasma sample were analysed to determine
the biomarker levels. The mean was calculated and used in
statistical analyses. Two pre-treatment baseline samples (collected
on separate days) were used to establish a mean pre-treatment
value. This concentration was assigned to the date that patient
was randomised in the trial and used as a reference point to
compare with the longitudinal sampling data. So as to retain as
much data as possible for analysis, samples which were analysed
and found to be above the upper limit of assay detection (ULOD)
were assigned a numerical value of 1 pg/mL above the ULOD.
Similarly, measurements which fell below the lower limit of assay
detection (LLOD) were assigned a numerical value of half of the
assay LLOD.
In order to explore the ability of the biomarkers to predict OS
based on greatest change from baseline, the percentage change
from baseline was calculated. Patients were ranked in order and
divided into three groups (tertiles) for comparison. The middle
tertile was set to 0, as this represented the ‘least change’ group.
The two extremes were compared with this.
The longitudinal sampling data were analysed using time-
varying covariate Cox models (TVC), this is a model that considers
the proportionality of hazards at any point in time. The HR is
obtained by integrating the longitudinal sampling data. All
statistical analysis was carried out at the Cancer Research UK,
and University College London (UCL) Cancer Trials Centre, London.
The means and 95% CI for each marker were plotted over time
by the treatment group to assess the change over time and the
difference between the treatment groups. In order to assess
whether a change in the marker at 3 months (the time point at
which the efﬁcacy evaluation took place) is associated with
survival outcomes, patients were grouped in terms of their
percentage change at 3 months, from baseline, into three groups
based on the distribution of the data (tertiles): lower, mid and
higher groups. The mid tertile group was used as the reference
group and represented the group of patients with the least
percentage change at 3 months from baseline. The lower tertile
group included the group of patients with a percentage change
decrease at 3 months from baseline. The higher tertile group
included the group of patients with a percentage increase at
3 months from baseline. For CTC count, a different approach was
used by grouping patients into no detectable CTCs at baseline and
at cycle 3 or any detectable CTCs at baseline and at cycle 3. These
groups were also compared using standard Cox model for PFS and
OS. Considering that the biomarkers were evaluated at different
time points and were variable over time, and that the aim of this
study was to evaluate the effect of the changing biomarkers over
time on the time-to-event outcomes, a TVC approach was
performed. The time-to-event endpoints considered were PFS
and OS. The TVC models were ﬁtted separately for each biomarker
at a time adjusting for treatment. Also, TVC models were ﬁtted
separately for each biomarker and the interaction between the
treatment and the marker were evaluated.
Considering that there were multiple biomarkers, backward
selection was applied to a Cox model including all biomarkers to
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Fig. 1 Changes in key biomarkers during treatment, split by treatment arm. The mean log of pg/ml of each biomarker, by treatment arm, is
shown at baseline (BL), during treatment cycles (C2-8), at the end of chemotherapy (End) and 1 month after the end of all treatment (+1m)
which equates to 1 month after disease progression has been documented. Panels a-g indicate markers that change similarly in both arms;
the cause may be CisGem chemotherapy or tumour burden (rather than Cediranib). Panels h and i show markers that occur at lower levels in
the circulation as a result of treatment with Cediranib. Panels j and k show markers that appear to be shed into the circulation as a result of
Cediranib. Error bars indicate 95% conﬁdence intervals. Number of patients at each time-point; BL=114, C2=96, C3=92, C4=90, C5=79,
C6=73, C7=71, C8=59, End=55, +1m=44
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identify a model with fewer, but relevant variables (parsimonious
multivariable Cox model), using a 5%-signiﬁcance level as a criteria
for the selection of a variable into the model. This was done for
PFS and OS Cox models with baseline markers (standard Cox
model) and TVC. All these models were adjusted for the treatment
group, which was considered a ﬁxed variable in the backward
selection procedure.
RESULTS
Patient information
A total of 124 patients (62 each in the cediranib and placebo
groups) with a median age of 65.1 years were recruited between
05 April 2011 and 28 Sept 2012. Details of the patient population
have been described previously.16 In summary, 104 (84%) patients
had metastatic disease (the remainder had locally-advanced
disease). The primary disease site was cholangiocarcinoma in 77
patients (62%), gallbladder cancer in 39 (31%) and ampulla of
Vater in 8 (6%). The median PFS was 8 months (95% CI 6.5–9.3) in
the cediranib group and 7.4 months (5.7–8.5) in the placebo group
(HR 0.93, 80% CI 0.74–1.19, P= 0.72). The median OS was
14.1 months (95% CI 10.2–16.4) in the cediranib group and
11.9 months (9.2–14.3) in the placebo group (HR 0.86, 80% CI
0.58–1.27, P= 0.44).
Dynamic biomarker changes in response to chemotherapy and
cediranib
Figure 1 describes the changing levels of the multiple biomarkers
in each arm over time and demonstrates that there were some
differences between the treatment groups. Panels a–g demon-
strate a decrease in circulating Ang1 and 2, FGFb, PDGFbb, VEGFC,
VEGFR1 and CK18 from the second time-point (prior to cycle 2, i.e.
post-cycle 1 of systemic treatment) and that this effect was lost at
the time-of-disease progression. This was independent of
cediranib, and is likely to be related to chemotherapy and/or
disease load. In contrast, panels h and i demonstrate a differential
effect of cediranib, preferentially reducing VEGFR2 and Tie2. This
difference was again lost at disease progression. Panels j and k
demonstrate a reverse effect, whereby cediranib was associated
with the preserved levels of circulating VEGFA and PIGF. The
effect-neutral biomarkers measured are shown in Supplementary
Figure S1 (HGF, IL6, IL8, KGF and SDF1b).
It is important to note that complete datasets are available only
for patients who were originally beneﬁtting from the treatment,
as, in patients whose disease progressed early, provision of further
research samples was discontinued.
Cediranib attenuates the detrimental outcome associated with
rising VEGFA
Changes at cycle 3 (C3) compared to the baseline for patients in
both treatment arms combined (i.e. chemotherapy with placebo
and chemotherapy with cediranib) are shown in Fig. 2a. Increased
levels of seven biomarkers at C3 describe a group of patients who
may beneﬁt from the treatment (with the exception of PDGFbb, in
whom, patients with decreased levels at C3 may beneﬁt less from
the treatment). The remaining biomarkers measured are shown in
Supplementary Figure S2A (CK18, HGF, IL6, IL8, PlGF, SDF1b,
VEGFR1 and VEGFR2).
In keeping with the effect seen at cycle 3 (above), patients with
increasing levels of VEGFA at any time in the TVC had a worse
outcome for both PFS and OS (Fig. 2b). However, in patients who
received cediranib, this detrimental outcome was attenuated. All
other biomarkers measured are shown in Supplementary
Figure S2B.
Multivariable models for biomarkers predictive of the outcome
Table 1 details multivariable models using the principle of
backward selection for biomarkers at baseline and when assessed
longitudinally using PFS and OS as outcomes. For the predictive
capacity of biomarkers at baseline, two different models are
generated for PFS and OS, respectively. These differences are likely
to be due to the short-term, rather than the longer-term,
biological impact. When considering the change in biomarkers
over time, rising levels of Ang2 are associated with longer OS (HR
0.77 [0.64–0.93] P= 0.007), but conversely increasing levels of
CK18 (a surrogate measure of disease burden/cell death) and
VEGFR2 (potentially a mechanism of resistance to therapy) are
associated with shorter OS (HR 1.07 [1.04–1.10] P < 0.001 and HR
1.12 [1.01–1.23] P= 0.02). PDGFbb does not feature in these
models as it did when previously described,16 primarily because
PDGFbb was previously analysed in two subsets (dichotomised at
Biomarker Forest plot NHR (95% CI)
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Fig. 2 a Relationship between % change from baseline at Cycle 3
and overall survival. % change from baseline was calculated, the
patients ranked in order and divided into three groups for
comparison. The middle tertile was set to 0, as this represents the
‘least change’ group, so the two extremities can be compared with
this. b Relationship between biomarker change during treatment
and outcome. VEGFA change from baseline during treatment was
evaluated using the time-varying covariate Cox model, which
included VEGFA as a continuous variable and considered units of
100pg/ml change in levels of circulating VEGFA during treatment. At
any given time-point, an increase in VEGFA in patients treated with
placebo is associated with a shorter PFS and OS. However, an
increase in VEGFA in patients treated with cediranib results in a
slightly longer PFS and has no effect on OS. The interaction
(treatment with biomarker) p-value is shown
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the median), rather than as a continuous variable. The tumour
markers CEA, CA19-9 and CA125 are not described, as no
longitudinal data was available for them. Supplementary Figure S3
shows the median and the range of all baseline circulating
biomarkers by the treatment arm.
CellSearch-detected circulating tumour cells are not predictive of
the beneﬁt from cediranib
Changes in CellSearch (CS)-detected CTCs do not predict for
patient outcomes for either PFS or OS, as illustrated in Fig. 3. Given
the low absolute numbers of CTCs, combined analysis of baseline
and cycle 3 CTC numbers did not improve the discrimination over
baseline counts alone. As such, assessment of on-treatment CTCs
did not predict the outcome.
Figure 4 summarises the data presented in Figs. 1–3.
DISCUSSION
The ABC-03 clinical trial assessed the effect of adding cediranib (an
oral VEGFR1, VEGFR2 and VEGFR3 receptor tyrosine kinase
inhibitor, with additional activity against PDGF receptors and c-
KIT) to cisplatin and gemcitabine chemotherapy in a double-bind,
placebo-controlled manner. The study did not meet its primary
endpoint (improvement in PFS); however, signals were observed
that would support further anti-angiogenesis approaches. Ele-
vated baseline levels of the tumour markers CEA and CA125 (in
addition to CA19-9), and total cytokeratin 18 and VEGFR2, as well
as CTCs were shown to be prognostic in ABC. Baseline plasma
PDGFbb concentrations might predict for the cediranib activity.
The second paper considers the change in circulating
biomarkers during the treatment; decrease in circulating Ang1,
Ang2, CK18, FGFb, PDGFbb, VEGFC and VEGFR1 was observed in
patient samples independent of treatment with cediranib.
Cediranib has previously been proposed to be causally linked
with a reduction in circulating VEGFR1, both in hepatocellular
carcinoma (HCC)22 and glioblastoma.23 However, both were
uncontrolled single-arm studies. In this prospective double-blind
placebo-controlled study, we have shown that this observation is
not, in fact, due to cediranib, rather due to thechemotherapy or
disease load. Similarly, a reduction in circulating plasma Ang2 has
been reported in uncontrolled studies in glioblastoma23 and
HCC.22 We demonstrated that this is also independent of cediranib
treatment and highlights the importance of a prospective
randomised study design in evaluating a potential biomarker.
Our observation of cediranib-induced reduction in VEGFR2 is in
keeping with previously published ﬁndings and its known
mechanism of action. This has been described following cediranib
monotherapy in solid tumours; phase I study,24 acute myeloid
leukaemia,25 glioblastoma,23 HCC,22 gastrointestinal stromal
tumour26 and in combination with lomustine in glioblastoma,27
carboplatin and paclitaxel in cervical cancer28 and geﬁtinib in solid
tumours.29 Placebo-controlled studies in colorectal cancer,30 renal
cell cancer,31 and breast cancer32 conﬁrmed that a reduction in
VEGFR2 was due to cediranib and was independent of the
companion therapies (primarily a combination with chemother-
apy, as in this study). We also observed that cediranib-induced
reduction in circulating Tie2 and similar ﬁndings have been
reported in glioblastoma,23 colorectal cancer30 and in solid
tumours treated with a cediranib–geﬁtinib combination.29
Patients with increasing levels of VEGFA at any time had a
worse outcome for both PFS and OS, in patients who received
cediranib, this detrimental outcome was attenuated. This, again,
is consistent with the known mechanism of action of cedir-
anib.16 This suggests that the changes in circulating VEGFA
correlates with the potential beneﬁt from treatment with
cediranib.
Using multivariable models for biomarkers predictive of out-
come, rising circulating levels of Ang2 were shown to be
Table 1. Cox multivariable model at baseline and using time-varying parameters
Biomarker (units)/amount of change
considered
Multivariable Cox models using baseline
biomarkers
Multivariable models using time-varying
biomarkers
Progression-free survival Overall survival Progression-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Ang2 (pg/ml)/1000 — — — — — — 0.77 (0.64–0.93) 0.007
CK18 (U/l)/100 1.03 (1.00–1.06) 0.029 1.08 (1.04–1.12) <0.001 1.05 (1.02–1.09) 0.001 1.07 (1.04–1.10) <0.001
CTC count/7.5ml 1.05 (1.01–1.08) 0.01 1.05 (1.02–1.09) 0.004 — — — —
FGFb (pg/ml)/100 0.96 (0.92–1.00) 0.04 — — — — — —
HGF (pg/ml)/100 — — 1.13 (1.05–1.20) 0.001 — — — —
IL6 (pg/ml)/10 — — 1.04 (1.01–1.07) 0.017 — — — —
IL8 (pg/ml)/10 — — 0.94 (0.90–0.98) 0.005 — — — —
SDF1b (pg/ml)/100 0.96 (0.93–0.99) 0.014 — — — — — —
VEGFC (pg/ml)/100 1.10 (1.01–1.21) 0.038 — — — — — —
VEGFR1 (pg/ml)/100 — — 0.77 (0.66–0.90) 0.001 — — — —
VEGFR2 (pg/ml)/1000 1.16 (1.04–1.3) 0.009 1.15 (1.02–1.29) 0.022 1.14 (1.04–1.24) 0.004 1.12 (1.01–1.23) 0.02
Treatment
Placebo 1.00 0.142 1.00 0.024 1.00 0.94 1.00 0.93
Cediranib 0.69 (0.42–1.13) 0.57 (0.35–0.93) 1.02 (0.68–1.52) 0.98 (0.63–1.52)
Each marker was chosen for inclusion using backward selection using signiﬁcance level criteria of 0.05.The ﬁnal best PFS Cox model at baseline contained
treatment, CK18, CTC count, FGFb, SDF1b, VEGFC and VEGFR2. Increase in all biomarkers (with the exception of FGFb and SDF1b) were associated with an
increased risk of disease progression.The ﬁnal best OS Cox model at baseline contained treatment, CK18, CTC count, HGF, IL6, IL8, VEGFR1 and VEGFR2.
Increase in all biomarkers (with the exception of IL8 and VEGFR1) were associated with an increased risk of death.The ﬁnal best PFS Cox model using time-
varying parameters, contained treatment, CK18 and VEGFR2. Increase in both biomarkers (with the exception of FGFb and SDF1b) were associated with an
increased risk of disease progression.The ﬁnal best OS Cox model using time-varying parameters, contained treatment, Ang2, CK18 and VEGFR2. Increase in all
biomarkers (with the exception of Ang2) were associated with an increased risk of death
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Fig. 3 Circulating tumour cells. Association between CTC count at baseline and Cycle 3 and PFS (a) and OS (b); patients who had CTCs
enumerated using Cell Search both at baseline (BL) and at the start of Cycle 3 of treatment, were divided into two categories; Group 1 had no
CTCs at BL and C3 (n=35) and Group 2 had at least 1 CTC at either BL or C3, or both time-points (n=22). The range of CTCs observed in this
patient set was 0-44, with a median of 0 and a mean of 2 CTCs. *As both of these curves overlap, this p-value may not be reliable. c Shows
change in CTC count (as absolute numbers at C3), shaded by best response. The hypothesis would be that the patients who had the biggest
decrease in CTCs, would have better outcomes (which is not the case). d Using the data collected from the n=56 patients who had CTCs
enumerated at both baseline and C3, this shows that combining baseline and C3 CTC counts appears less discriminatory than considering
baseline CTC counts alone
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associated with longer OS. Ang2 is a growth factor ligand of the
Tie family of protein receptor tyrosine kinases.33 Ang2 promotes
the dissociation of pericytes and loosens the cellular junctions,
which results in unstable blood vessels.34 Increasing levels of
circulating Ang2 in this setting would appear to be indicative of
effective tumour destabilisation.
Conversely, rising levels of CK18 were associated with a
shorter OS. Cancers of epithelial origin are known to contain
relatively large intracellular pools of soluble and insoluble
cytokeratins. However, during necrotic and apoptotic cell death,
CK18 and other cytokeratins are released into the blood in either
their intact or their caspase-cleaved forms, where they remain
relatively stable in the circulation of patients with cancer.35 CK18
is proposed as a surrogate measure of disease burden/drug-
induced cell death,36,37 and it would appear that rising levels in
this patient population is indicative of impending disease
progression.
Similarly, rising levels of VEGFR2 (in all patients) were associated
with a shorter OS. As a target of cediranib, it is not unexpected to
observe a fall in levels of circulating VEGFR2, but it is interesting to
note that an increase in the levels in all patients is associated with
disease progression and suggests a potential mechanism of
resistance to chemotherapy.
Whilst we reported that CellSearch-identiﬁed CTCs were
prognostic at baseline in ABC-03,17 the data presented here does
not support their role as predictive biomarkers for cediranib. A
Figure 1 summary   Change by treatment arm
including appendix Figure 1
Decreased
Ang1 & 2
CK18
FGFb
PDGFbb
VEGFC
VEGFR1
Ang1 & 2
FGFb
KGF
Tie2
VEGFA & C
+ placebo = detriment
Baseline
Detriment
CK 18
CTCs
HGF
IL6
IL8
SDF1b
VEGFC
VEGFR2
Benefit Detriment
CK 18
VEGFR2
Benefit
Ang2FGFb
High Time-varying Increasing
+ Cediranib = no difference
Change at C3 = longer OS
Increasing VEGFA during treatment
Increase Decrease
PDGFbb
In both arms + Cediranib
VEGFR2
Tie2
+ Cediranib
VEGFA
PIGF
Increased Unclear
In both arms
HGF
KGF
SDF1b
IL6 & 8
Figure 2A summary   Early change & OS
Figure 2B summary   Change by treatment arm
Figure 3 summary   Multivariable analysis & OS
Fig. 4 Summary. Figure 1 shows markers which change with treatment, split by treatment arm; Ang1&2, FGFb, PDGFbb, VEGFC and
VEGFR1 show patterns of change which are similar in both placebo and cediranib arms. Four proteins show different patterns of change
between the two treatment arms; VEGFR2 and Tie2 decrease + Cediranib, VEGFA and PlGF increase + Cediranib. Appendix Figure 1 shows
changes with treatment which occurred in HGF, IL6, IL8, KGF and SDF1b, which do not show obvious patterns of change. This information may
be relevant when designing future trials. Figure 2 examines how change in biomarkers is related to length of OSIn all patients, increases in
Ang1&2, FGFb, KGF, Tie2, VEGFA and VEGFC at C3 was associated with longer OS. Conversely, decrease s in PDGFbb were associated with
longer OS. Change in VEGFA is the only marker which predicts outcome (PFS and OS) differently by treatment arm (increasing VEGFA in the
placebo arm is associated with a worse outcome, but this not seen in patients in the Cediranib arm). Table 1 summarises univariate and
multivariable Cox models using time-varying parameters for PFS and OS
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limitation of these data is that only a subgroup (43 patients for the
CTC subgroup) had complete data. Moreover, the CellSearch
platform captures only EpCam-expressing CTCs; in many epithelial
cancer types, this represents only a subset of CTCs not measuring,
for example, the CTCs undergoing epithelial-to-mesenchymal
transition. Further studies would be required using marker-
independent CTC platforms, which accommodate phenotypic
heterogeneity coupled with molecular analysis of DNA proﬁles of
the isolated CTC candidates, to allow detailed evaluation of their
utility in the clinical setting. Future studies would also beneﬁt from
the collection of the genomic proﬁling data, which may provide
methods for treatment selection.
This translational component to the clinical study was set out to
evaluate the biomarkers usefulness, as suggested by others.38
These data provide additional information about a panel of
circulating biomarkers, which may predict the beneﬁt from the
combination of chemotherapy and cediranib.
These data suggest that the treatment with cediranib may
attenuate the increased risk of progression and death associated
with high circulating levels of VEGFA. It is not known whether this
is true for other VEGFA inhibitors such as bevacizumab.
The strength of this study is the prospective evaluation of the
sequential biomarker analysis in a randomised cohort of patients
against a control, as described in the Cancer Research UK
biomarker roadmap (www.cruk.org.uk). We have been able to
differentiate between chemotherapy- and cediranib-related
effects, and have demonstrated that week 9 (cycle 3) is a suitable
time point for the biomarker estimation.
The primary limitation of this study was the necessary “self-
selection” of patients for whom the data were available, as only
patients who were deemed to have derived clinical beneﬁt (by
the absence of disease progression on treatment) contributed
longitudinal biomarker data. In addition, this biomarker
substudy serves as an exploratory dataset that was not
powered a priori to identify the robust subgroups and not
adjusted for multiple testing; the ﬁndings would need to be
validated in an independent dataset, according to the REMARK
guidelines.39
CONCLUSION
Unravelling the complexity of circulating biomarkers is best
achieved though prospective randomised trials such as ABC-03.
These data propose that the detrimental outcome observed on PFS
and OS associated with circulating VEGFA levels in patients with
advanced biliary tract cancer treated with cisplatin and gemcitabine
may be attenuated by cediranib. This is in keeping with its known
mechanism of action. The role of VEGF inhibition requires further
evaluation to identify and validate biomarker-deﬁned potentially
responsive subgroups. Surrogate measures of tumour burden (rising
CK18) and potential treatment resistance (rising VEGFR2) were
associated with worse outcomes and warrant validation.
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